Characterization of a novel oncogenic K-ras mutation in colon cancer

Biochemical and Biophysical Research Communications

Volumn 352, Issue 3, 2007, Pages 728-732

  Akagi, Kiwamu ^a   Uchibori, Ryosuke ^a   Yamaguchi, Kensei ^a   Kurosawa, Keiko ^a   Tanaka, Yoichiro ^a   Kozu, Tomoko ^a  

^a SAITAMA CANCER CENTER   (Japan)

Author keywords

Colorectal cancer; K ras; Mutation; Signaling; Transformation

Indexed keywords

LEUCINE; PHENYLALANINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CARCINOGENICITY; CELL MUTANT; CHEMICAL ANALYSIS; COLON CARCINOMA; CONTROLLED STUDY; EMBRYO; GENE MUTATION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; TUMOR GROWTH; WILD TYPE;

AMINO ACID SEQUENCE; BASE SEQUENCE; COLONIC NEOPLASMS; GENES, RAS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM PROTEINS; RAS PROTEINS;

MUS MUSCULUS;

EID: 33845318551     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.11.091     Document Type: Article

References (27)

1. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 (1996) 159-170
2. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
3. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., and Bos J.L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319 (1988) 525-532
4. Lowy D.R., and Willumsen B.M. Function and regulation of ras. Annu. Rev. Biochem. 62 (1993) 851-891
5. Vetter I.R., and Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science 294 (2001) 1299-1304
6. Donovan S., Shannon K.M., and Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim. Biophys. Acta 1602 (2002) 23-45
7. Campbell S.L., Khosravi-Far R., Rossman K.L., Clark G.J., and Der C.J. Increasing complexity of Ras signaling. Oncogene 17 (1998) 1395-1413
8. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3 (2003) 11-22
9. Malumbres M., and Barbacid M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3 (2003) 459-465
10. Friday B.B., and Adjei A.A. K-ras as a target for cancer therapy. Biochim. Biophys. Acta 1756 (2005) 127-144
11. Adjei A.A. Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. 93 (2001) 1062-1074
12. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 49 (1989) 4682-4689
13. Dergham S.T., Dugan M.C., Kucway R., Du W., Kamarauskiene D.S., Vaitkevicius V.K., Crissman J.D., and Sarkar F.H. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int. J. Pancreatol. 21 (1997) 127-143
14. Wang J.Y., Lian S.T., Chen Y.F., Yang Y.C., Chen L.T., Lee K.T., Huang T.J., and Lin S.R. Unique K-ras mutational pattern in pancreatic adenocarcinoma from Taiwanese patients. Cancer Lett. 180 (2002) 153-158
15. Shibata D., Almoguera C., Forrester K., Dunitz J., Martin S.E., Cosgrove M.M., Perucho M., and Arnheim N. Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res. 50 (1990) 1279-1283
16. Bos J.L., Fearon E.R., Hamilton S.R., Verlaan-de Vries M., van Boom J.H., van der Eb A.J., and Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature 327 (1987) 293-297
17. Kressner U., Bjorheim J., Westring S., Wahlberg S.S., Pahlman L., Glimelius B., Lindmark G., Lindblom A., and Borresen-Dale A.L. Ki-ras mutations and prognosis in colorectal cancer. Eur. J. Cancer 34 (1998) 518-521
18. Moerkerk P., Arends J.W., van Driel M., de Bruine A., de Goeij A., and ten Kate J. Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res. 54 (1994) 3376-3378
19. Mascaux C., Iannino N., Martin B., Paesmans M., Berghmans T., Dusart M., Haller A., Lothaire P., Meert A.P., Noel S., Lafitte J.J., and Sculier J.P. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br. J. Cancer 92 (2005) 131-139
20. Malats N., Porta M., Pinol J.L., Corominas J.M., Rifa J., and Real F.X. Ki-ras mutations as a prognostic factor in extrahepatic bile system cancer. PANK-ras I Project Investigators. J. Clin. Oncol. 13 (1995) 1679-1686
21. Cuatrecasas M., Villanueva A., Matias-Guiu X., and Prat J. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 79 (1997) 1581-1586
22. Breivik J., Meling G.I., Spurkland A., Rognum T.O., and Gaudernack G. K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br. J. Cancer 69 (1994) 367-371
23. Brink M., de Goeij A.F., Weijenberg M.P., Roemen G.M., Lentjes M.H., Pachen M.M., Smits K.M., de Bruine A.P., Goldbohm R.A., and van den Brandt P.A. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24 (2003) 703-710
24. Lin S.R., Tsai J.H., Yang Y.C., and Lee S.C. Mutations of K-ras oncogene in human adrenal tumours in Taiwan. Br. J. Cancer 77 (1998) 1060-1065
25. Lin S.R., Hsu C.H., Tsai J.H., Wang J.Y., Hsieh T.J., and Wu C.H. Decreased GTPase activity of K-ras mutants deriving from human functional adrenocortical tumours. Br. J. Cancer 82 (2000) 1035-1040
26. Tsukuda K., Tanino M., Soga H., Shimizu N., and Shimizu K. A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma. Biochem. Biophys. Res. Commun. 278 (2000) 653-658
27. Guerrero S., Casanova I., Farre L., Mazo A., Capella G., and Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 60 (2000) 6750-6756